Upon enrollment, patients undergo comprehensive genomic testing to identify specific mutations and other molecular characteristics of their AML. Based on these findings, patients are assigned to one of several treatment arms within the trial, each investigating a different targeted therapy. This personalized approach aims to provide more effective and less toxic treatments compared to traditional chemotherapy.
